Immunomedics Inc

Immunomedics — Proxy Contest (December 2016)

24 slides from Immunomedics's proxy contest presentation, Dec 14, 2016

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation, in addition to historical information, contains certain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties, and actual results could differ mat

  2. Slide 2: Agenda

    Agenda 3 Executive Summary Overview and Clinical Update Strategy to Create Long-Term Stockholder Value

  3. Slide 3: Agenda

    Agenda * Executive Summary * Overview and Clinical Update * Strategy to Create Long-Term Stockholder Value

  4. Slide 4: Board and Management committed to acting in best interests of stockholders

    Immunomedics’ Board of Directors and Management are committed to acting in the best interests of the Company and all stockholders. The Company’s top priorities are: Filing Accelerated Approval Biologic License Application (BLA) for IMMU-132 for therapy of patients with advanced triple-negative breas

  5. Slide 5: Well positioned to execute on the Company's strategy

    Well positioned to execute on the Company’s strategy: The Company has to-date enrolled over 400 patients with diverse metastatic cancers, being one of the first to study patients in a Phase 1/2 "basket trial design" that tests the investigational agent in diverse cancer types, thus quickly identifyi

  6. Slide 6: Addressing stockholder needs

    Addressing stockholder needs Retained Greenhill & Co., LLC, to serve as a strategic advisor, to assist in out-licensing efforts initially related to IMMU-132 and to handle inbound interest for earlier stage assets Continue negotiations with third parties interested in licensing IMMU-132 under differ

  7. Slide 7: Overview and Clinical Update

    Overview and Clinical Update 8

  8. Slide 8: Overview and Financial Highlights

    9 Overview and Financial Highlights Basic shares outstanding 106 million Market capitalization $391 million Debt (convertible senior notes) $100 million Cash, cash equivalents and marketable securities $60 million Forecast FY 2017 annual cash burn (6/30/17) $42-44 million 1 Note: Market data as of 1

  9. Slide 9: Multiple advanced clinical phase programs focused on cancers with unmet need

    Multiple advanced clinical phase programs focused on cancers with unmet need Validated first-in-class antibody-drug conjugate (ADC) platform technology for solid cancer therapy Lead ADC (IMMU-132) granted Breakthrough Therapy Designation (BTD) from FDA in metastatic TNBC Advanced important new produ

  10. Slide 10: Robust Pipeline of Antibody-Based Therapies

    11 Research/Preclinical Phase 1 Phase 2 Phase 3 Sacituzumab govitecan/IMMU-132 (anti-Trop-2-SN-38 antibody-drug conjugate) Metastatic triple-negative breast cancer FDA granted BTD Epratuzumab (humanized anti-CD22) Labetuzumab govitecan/IMMU-130 (anti-CEACAM5-SN-38 antibody-drug conjugate) Metastatic

  11. Slide 11: Immunomedics' Next Generation ADC Technology Platform

    Potential characteristics of difficult-to-treat tumors Not responsive to prior therapies Protected by surrounding layer of connective tissue Often metastatic, even at initial diagnosis Components of IMMU’s ADC platform Highly specific MAbs that are targeted to cancer cells Specially designed “payloa

  12. Slide 12: What makes IMMU's ADCs different?

    What makes IMMU’s ADCs different? Highly cancer-specific antibodies based on 30 years of experience Utilize moderately potent payloads: increased therapeutic index Utilize MAb with immunotherapy functions (IMMU-132) Utilize MAb with therapeutic activity due to metabolic signaling functions (IMMU-140

  13. Slide 13: Mechanism of action

    Mechanism of action Binds Trop-2, which is highly expressed on many epithelial cancer cells and may be an oncogene Internalizes rapidly into target cancer cells when bound Delivers enhanced SN-38 concentrations at or in the tumor Shows immunotherapeutic action in laboratory tests Breakthrough Therap

  14. Slide 14: Meaningful responses in patients having multiple prior therapies

    15 Meaningful responses in patients having multiple prior therapies Phase 1 / 2 clinical trials IMMU-132: Summary Efficacy (Patients with at least one post-treatment response evaluation) TNBC results as of May 2016; NSCLC and SCLC results presented at 2016 ASCO; UC results presented at PEGS Boston 2

  15. Slide 15: IMMU-132: Best Response from TNBC Patients

    16 IMMU-132: Best Response from TNBC Patients 60 assessable (10 mg/kg) Objective response (CR + PR) = 33% Confirmed response (RECIST 1.1) = 28% 62 patients enrolled with 2 or more prior lines of therapy that included a taxane 2 excluded because <2 doses given. Median # prior chemotherapies = 5 (rang

  16. Slide 16: IMMU-132: Updated Clinical Development in TNBC

    Single-arm Phase 2 study Completing the enrollment of 100 TNBC patients with at least 2 prior therapies for metastatic disease before the end of 2016 Third-party ‘blinded” confirmation of response assessment ongoing Phase 3 confirmatory trial Validation of commercial-scale manufacturing by outside C

  17. Slide 17: IMMU-132 Meaningful Anticipated Upcoming Events

    18 Event Expected Timing (Calendar Year) Publish/present updated Phase 2 data in metastatic TNBC 4Q 2016 Complete Phase 2 patient enrollment in metastatic TNBC 4Q 2016 Submit additional breakthrough therapy applications 1Q 2017 Completion of partnering deal for IMMU-132 1Q 2017 Initiate Phase 3 pivo

  18. Slide 18: Strategy to Create Long-Term Stockholder Value

    Strategy to Create Long- Term Stockholder Value 19

  19. Slide 19: Achieved critical objectives related to IMMU-132

    Achieved critical objectives related to IMMU-132 in TNBC: Delivered positive Phase 2 clinical trial results of IMMU-132 in patients with metastatic triple-negative breast cancer (TNBC), which were presented at the 2016 SABCS and submitted for publication Achieved timetable for the manufacturing of c

  20. Slide 20: Expanded ADC program to address 90% of human cancers

    Expanded ADC program to potentially address 90% of human cancers by incidence Created a novel IMMU-114-SN-38 conjugate (IMMU-140) for the treatment of blood cancers Preclinical study presented at the 2015 American Society of Hematology demonstrated enhanced antitumor activity over IMMU-114 in mouse

  21. Slide 21: Enhanced executive leadership and strengthened liquidity

    Enhanced executive leadership with appointment of Michael R. Garone, MBA, as Vice President, Finance, and Chief Financial Officer, in June 2016 Previously served as CFO, Corporate Secretary and interim CEO of Emisphere Technologies, Inc., a commercial stage, specialty pharmaceutical company, as inte

  22. Slide 22: Strong Track Record of Clinical and Regulatory Progress

    23 Strong Track Record of Clinical and Regulatory Progress Significant Regulatory Progress The Company's regulatory and clinical groups, as well as the preclinical CMC scientists, have had numerous interactions with FDA and the European EMA on the development of IMMU-132 An end-of-Phase 2 meeting wi

  23. Slide 23: Strong progress toward near-term milestones

    Immunomedics has made strong progress toward achieving a number of critical near-term milestones, including: Preparing to submit a Biological License Application (BLA) to the FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017 Nearing completion of enrolling 100 T

  24. Slide 24: Clear Strategy for Continued Value Creation

    4 Clear Strategy for Continued Value Creation + Immunomedics has made strong progress toward achieving a number of cr al near-term milestones, including: Preparing to submit a Biological License Application (BLA) to the FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in m

Immunomedics — Proxy Contest (December 2016) on 6ix